

DAFTAR PUSTAKA

- Abedini, M.R., Qiu, Q., Yan, X. and Tsang, B.K. (2004) 'Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro', *Oncogene*, 23(42), pp. 6997–7004. Available at: <https://doi.org/10.1038/sj.onc.1207925>.
- Adrian Calin, G., Sevignani, C., Dan Dumitru, C., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M. and Croce, C.M. (2004) *Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers*. Available at: www.gene.ucl.ac.uk.
- Al-Alem, L.F., Baker, A.T., Pandya, U.M., Eisenhauer, E.L. and Rueda, B.R. (2019) 'Understanding and targeting apoptotic pathways in ovarian cancer', *Cancers*. MDPI AG. Available at: <https://doi.org/10.3390/cancers11111631>.
- Anastasiadou, E., Messina, E., Sanavia, T., Mundo, L., Farinella, F., Lazzi, S., *et al.* (2021) 'Mir-200c-3p contrasts pd-11 induction by combinatorial therapies and slows proliferation of epithelial ovarian cancer through downregulation of β -catenin and c-myc', *Cells*, 10(3), pp. 1–21. Available at: <https://doi.org/10.3390/cells10030519>.
- Bast, R.C., Hennesy, B. and Mills, G.B. (2009) 'The biology of ovarian cancer: new opportunities for translation', *Nature Reviews Cancer*, 9(6), pp. 415–428. Available at: <https://doi.org/10.1038/nrc2644>.
- Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D.W., Dao, F., *et al.* (2011) 'Integrated genomic analyses of ovarian carcinoma', *Nature*, 474(7353), pp. 609–615. Available at: <https://doi.org/10.1038/nature10166>.
- Bertucci, A., Kim, K.H., Kang, J., Zuidema, J.M., Lee, S.H., Kwon, E.J., Kim, D., Howell, S.B., Ricci, F., Ruoslahti, E., Jang, H.J. and Sailor, M.J. (2019) 'Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy', *ACS Applied Materials and Interfaces*, 11(27), pp. 23926–23937. Available at: <https://doi.org/10.1021/acsami.9b07980>.
- Braga, E.A., Fridman, M. V. and Kushlinskii, N.E. (2017) 'Molecular mechanisms of ovarian carcinoma metastasis: Key genes and regulatory microRNAs', *Biochemistry (Moscow)*. Maik Nauka Publishing / Springer SBM, pp. 529–541. Available at: <https://doi.org/10.1134/S0006297917050017>.
- Brozovic, A., Duran, G.E., Wang, Y.C., Francisco, E.B. and Sikic, B.I. (2015) 'The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian

OVCAR-3 and MES-OV cells', *Molecular Oncology*, 9(8), pp. 1678–1693.

Available at: <https://doi.org/10.1016/j.molonc.2015.04.015>.

Cao, Q., Lu, K., Dai, S., Hu, Y. and Fan, W. (2014) *Original Article Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer, Int J Clin Exp Pathol*. Available at: www.ijcep.com/.

Castells, M., Milhas, D., Gandy, C., Thibault, B., Rafii, A., Delord, J.P. and Couderc, B. (2013) 'Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation', *Cell Death and Disease*, 4(10), pp. e887-9. Available at: <https://doi.org/10.1038/cddis.2013.384>.

Chan, J.K., Blansit, K., Kiet, T., Sherman, A., Wong, G., Earle, C. and Bourguignon, L.Y.W. (2014) 'The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer', *Gynecologic Oncology*, 132(3), pp. 739–744. Available at: <https://doi.org/10.1016/j.ygyno.2014.01.034>.

Chang, H., Zhang, X., Li, B. and Meng, X. (2020) 'MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis', *Cancer Medicine*, 9(17), pp. 6377–6386. Available at: <https://doi.org/10.1002/cam4.3126>.

Chen, J., Hu, C. and Pan, P. (2017) 'Extracellular vesicle microRNA transfer in lung diseases', *Frontiers in Physiology*. Frontiers Media S.A. Available at: <https://doi.org/10.3389/fphys.2017.01028>.

Chen, S.N., Chang, R., Lin, L. Te, Chern, C.U., Tsai, H.W., Wen, Z.H., Li, Y.H., Li, C.J. and Tsui, K.H. (2019) 'MicroRNA in ovarian cancer: Biology, pathogenesis, and therapeutic opportunities', *International Journal of Environmental Research and Public Health*, 16(9), pp. 1–14. Available at: <https://doi.org/10.3390/ijerph16091510>.

Chen, X., Mangala, L.S., Mooberry, L., Bayraktar, E., Dasari, S.K., Ma, S., *et al.* (2019) 'Identifying and targeting angiogenesis-related microRNAs in ovarian cancer', *Oncogene*, 38(33), pp. 6095–6108. Available at: <https://doi.org/10.1038/s41388-019-0862-y>.

Chen, Y., Zhang, L. and Hao, Q. (2013) 'Candidate microRNA biomarkers in human epithelial ovarian cancer: Systematic review profiling studies and experimental validation', *Cancer Cell International*, 13(1), p. 1. Available at: <https://doi.org/10.1186/1475-2867-13-86>.

Chen, Y.N., Ren, C.C., Yang, L., Nai, M.M., Xu, Y.M., Zhang, F. and Liu, Y. (2019) 'MicroRNA let-7d-5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1', *International Journal of Oncology*, pp. 1771–1784. Available at: <https://doi.org/10.3892/ijo.2019.4731>.

- Chetry, M., Thapa, S., Hu, X., Song, Y., Zhang, J., Zhu, H. and Zhu, X. (2018) 'The role of galectins in tumor progression, treatment and prognosis of gynecological cancers', *Journal of Cancer*, 9(24), pp. 4742–4755. Available at: <https://doi.org/10.7150/jca.23628>.
- Choi, P.W., Bahrapour, A., Ng, S.K., Liu, S.K., Qiu, W., Xie, F., Kuo, W.P., Kwong, J., Hales, K.H., Hales, D.B., Wong, K.K., Norwitz, E.R., Chow, C.K., Berkowitz, R.S. and Ng, S.W. (2020) 'Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer', *Scientific Reports*, 10(1). Available at: <https://doi.org/10.1038/s41598-020-77068-0>.
- Christiansen, M.N., Chik, J., Lee, L., Anugraham, M., Abrahams, J.L. and Packer, N.H. (2014) 'Cell surface protein glycosylation in cancer', *Proteomics*, 14(4–5), pp. 525–546. Available at: <https://doi.org/10.1002/pmic.201300387>.
- Chu, Y.L., Li, H., Ng, P.L.A., Kong, S.T., Zhang, H., Lin, Y., *et al.* (2020) 'The potential of circulating exosomal RNA biomarkers in cancer', *Expert Review of Molecular Diagnostics*, 20(7), pp. 665–678. Available at: <https://doi.org/10.1080/14737159.2020.1745064>.
- Chung, Y.W., Bae, H.S., Song, J.Y., Lee, J.K., Lee, N.W., Kim, T. and Lee, K.W. (2013) 'Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patient', *International Journal of Gynecological Cancer*, 23(4), pp. 673–679. Available at: <https://doi.org/10.1097/IGC.0b013e31828c166d>.
- Cochrane, D.R., Howe, E.N., Spoelstra, N.S. and Richer, J.K. (2010) 'Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers', *Journal of Oncology*, 2010, pp. 1–12. Available at: <https://doi.org/10.1155/2010/821717>.
- Cochrane, D.R., Spoelstra, N.S., Howe, E.N., Nordeen, S.K. and Richer, J.K. (2009) 'MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents', *Molecular Cancer Therapeutics*, 8(5), pp. 1055–1066. Available at: <https://doi.org/10.1158/1535-7163.MCT-08-1046>.
- Dahiya, N. and Morin, P.J. (2010) 'MicroRNAs in ovarian carcinomas', *Endocrine-Related Cancer*. Available at: <https://doi.org/10.1677/ERC-09-0203>.
- Dastmalchi, N., Baradaran, B., Banan Khojasteh, S.M., Hosseinpourfeizi, M. and Safaralizadeh, R. (2021) 'miR-424: A novel potential therapeutic target and prognostic factor in malignancies', *Cell Biology International*. John Wiley and Sons Inc, pp. 720–730. Available at: <https://doi.org/10.1002/cbin.11530>.
- Davidson, B., Tropé, C.G. and Reich, R. (2014) 'The clinical and diagnostic role of microRNAs in ovarian carcinoma', *Gynecologic Oncology*, 133(3), pp. 640–646. Available at: <https://doi.org/10.1016/j.ygyno.2014.03.575>.

- Deb, B., Uddin, A. and Chakraborty, S. (2018) 'mikroRNAs and ovarian cancer: An overview', *Journal of Cellular Physiology*, 233(5), pp. 3846–3854. Available at: <https://doi.org/10.1002/jcp.26095>.
- Doench, J.G., Petersen, C.P. and Sharp, P.A. (2003) 'siRNAs can function as mikroRNAs', *Genes & Development*, 17(4), pp. 438–442. Available at: <https://doi.org/10.1101/gad.1064703>.
- Duffy, M.J., Bonfrer, J.M., Kulpa, J., Rustin, G.J.S., Soletormos, G., Torre, G.C., Tuxen, M.K. and Zwirner, M. (2005) 'CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.', *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*, 15(5), pp. 679–91. Available at: <https://doi.org/10.1111/j.1525-1438.2005.00130.x>.
- Dwivedi, S.K.D., Mustafi, S.B., Mangala, L.S., Jiang, D., Pradeep, S., Rodriguez-Aguayo, C., Ling, H., Ivan, C., Mukherjee, P., Calin, G.A., Lopez-Berestein, G., Sood, A.K. and Bhattacharya, R. (2016) 'Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.', *Oncotarget*, 7(12), pp. 15093–104. Available at: <https://doi.org/10.18632/oncotarget.7618>.
- Ebert, M.S., Neilson, J.R. and Sharp, P.A. (2013) 'MicroRNA sponges: competitive inhibitors of small RNAs i', *Nat Methods*, 4(9). Available at: <https://doi.org/10.1038/nmeth1079>.
- Echevarría-Vargas, I.M., Valiyeva, F. and Vivas-Mejía, P.E. (2014) 'Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway', *PLoS ONE*, 9(5). Available at: <https://doi.org/10.1371/journal.pone.0097094>.
- Eitan, R., Kushnir, M., Lithwick-Yanai, G., David, M. Ben, Hoshen, M., Glezerman, M., Hod, M., Sabah, G., Rosenwald, S. and Levavi, H. (2009) 'Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients', *Gynecologic Oncology*, 114(2), pp. 253–259. Available at: <https://doi.org/10.1016/j.ygyno.2009.04.024>.
- El-kott, A.F., Shati, A.A., Ali Al-kahtani, M. and Alharbi, S.A. (2019) 'The apoptotic effect of resveratrol in ovarian cancer cells is associated with downregulation of galectin-3 and stimulating miR-424-3p transcription', *Journal of Food Biochemistry*, 43(12), pp. 1–11. Available at: <https://doi.org/10.1111/jfbc.13072>.
- Esin, E., Bilgetekin, İ., Başal, F.B., Duran, A.O., Demirci, U. and Öksüzoğlu, B. (2019) 'Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies', *Journal of Oncological Sciences*, 5(3), pp. 96–99. Available at: <https://doi.org/10.1016/j.jons.2019.09.002>.

- Feinbaum, R., Ambros, V. and Lee, R. (2004a) 'The *C. elegans* Heterochronic Gene *lin-4* Encodes Small RNAs with Antisense Complementarity to *lin-14*', *Cell*, 116(116), pp. 843–854.
- Feinbaum, R., Ambros, V. and Lee, R. (2004b) 'The *C. elegans* Heterochronic Gene *lin-4* Encodes Small RNAs with Antisense Complementarity to *lin-14*', *Cell*, 116(116), pp. 843–854.
- Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I and Bray F (2024) *Statistics at a glance, 2022 Top 5 most frequent cancers (5-year)*. Available at: <https://gco.iarc.who.int/today> (Accessed: 1 May 2024).
- Ferneza, S., Fetsych, M., Shuliak, R., Makukh, H., Volodko, N., Yarema, R. and Fetsych, T. (2021) 'Clinical significance of microRNA-200 and let-7 families expression assessment in patients with ovarian cancer', *ecancermedicalsecience*, 15. Available at: <https://doi.org/10.3332/ECANCER.2021.1249>.
- Finch, A., Shaw, P., Rosen, B., Murphy, J., Narod, S.A. and Colgan, T.J. (2006) 'Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers', *Gynecologic Oncology*, 100(1), pp. 58–64. Available at: <https://doi.org/10.1016/j.ygyno.2005.06.065>.
- Frenzel, A., Labi, V., Chmielewski, W., Ploner, C., Geley, S., Fiegl, H., Tzankov, A. and Villunger, A. (2010) 'Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad', *Blood*, pp. 995–1005. Available at: <https://doi.org/10.1182/blood-2009-03-212670>.
- Friedländer, M.R., Lizano, E., Houben, A.J.S., Bezdan, D., Báñez-Coronel, M., Kudla, G., Mateu-Huertas, E., Kagerbauer, B., González, J., Chen, K.C., LeProust, E.M., Martí, E. and Estivill, X. (2014) 'Evidence for the biogenesis of more than 1,000 novel human microRNAs', *Genome Biology*, 15(4), pp. 1–17. Available at: <https://doi.org/10.1186/gb-2014-15-4-r57>.
- Gadducci, A., Sergiampietri, C., Lanfredini, N. and Guiggi, I. (2014) 'Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research', *Gynecological Endocrinology*, 30(4), pp. 266–271. Available at: <https://doi.org/10.3109/09513590.2013.871525>.
- Galluzzi, L., Vitale, I., Aaronson, S.A., Abrams, J.M., Adam, D., Agostinis, P., *et al.* (2018) 'Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018', *Cell Death and Differentiation*, 25(3), pp. 486–541. Available at: <https://doi.org/10.1038/s41418-017-0012-4>.

- Gao, L. and Jiang, F. (2016) 'MicroRNA (mikroRNA) Profiling', in *Grützmann R., Pilarsky C. (eds) Cancer Gene Profiling. Methods in Molecular Biology*, pp. 151–161. Available at: https://doi.org/10.1007/978-1-4939-3204-7_8.
- Garcia-Silva, M.R., Cabrera-Cabrera, F., Güida, M.C. and Cayota, A. (2012) 'Hints of tRNA-derived small RNAs role in RNA silencing mechanisms', *Genes*, 3(4), pp. 603–614. Available at: <https://doi.org/10.3390/genes3040603>.
- Gasparri, M.L., Bardhi, E., Ruscito, I., Papadia, A., Farooqi, A.A., Marchetti, C., Bogani, G., Ceccacci, I., Mueller, M.D. and Benedetti Panici, P. (2017) 'PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?', *Geburtshilfe und Frauenheilkunde*. Georg Thieme Verlag, pp. 1095–1103. Available at: <https://doi.org/10.1055/s-0043-118907>.
- Ghafouri-Fard, S., Shoorei, H. and Taheri, M. (2020) 'mikroRNA profile in ovarian cancer', *Experimental and Molecular Pathology*, 113, p. 104381. Available at: <https://doi.org/10.1016/j.yexmp.2020.104381>.
- Giornelli, G.H. (2016) 'Management of relapsed ovarian cancer: a review', *SpringerPlus*. SpringerOpen. Available at: <https://doi.org/10.1186/s40064-016-2660-0>.
- Gokulnath, P., de Cristofaro, T., Manipur, I., Di Palma, T., Soriano, A.A., Guarracino, M.R. and Zannini, M. (2020) 'Long non-coding RNA HAND2-AS1 acts as a tumor suppressor in high-grade serous ovarian carcinoma', *International Journal of Molecular Sciences*, 21(11), pp. 1–16. Available at: <https://doi.org/10.3390/ijms21114059>.
- Gong, J., Xu, X., Zhang, X. and Zhou, Y. (2020) 'Circular RNA-9119 suppresses in ovarian cancer cell viability via targeting the microRNA-21-5p-PTEN-Akt pathway', *Aging*, 12(14), pp. 14314–14328. Available at: <https://doi.org/10.18632/aging.103470>.
- Gregory, R.I., Chendrimada, T.P., Cooch, N. and Shiekhattar, R. (2005) 'Human RISC couples microRNA biogenesis and posttranscriptional gene silencing', *Cell*, 123(4), pp. 631–640. Available at: <https://doi.org/10.1016/j.cell.2005.10.022>.
- Guo, R. and Qin, Y. (2020) 'LEMD1-AS1 suppresses ovarian cancer progression through regulating MiR-183-5p/tp53 axis', *OncoTargets and Therapy*, 13, pp. 7387–7398. Available at: <https://doi.org/10.2147/OTT.S250850>.
- Hammond, S.M. (2015) 'An overview of microRNAs', *Advanced Drug Delivery Reviews*, 87, pp. 3–14. Available at: <https://doi.org/10.1016/j.addr.2015.05.001>.
- Hanahan, D. and Weinberg, R.A. (2011) 'Hallmarks of cancer: The next generation', *Cell*, 144(5), pp. 646–674. Available at: <https://doi.org/10.1016/j.cell.2011.02.013>.
- Hassan, H., Salem, M., Gouida, M. and El-Azab, K. (2018) 'Comparative expression of caspases and annexin v in benign and malignant ovarian tumors', *Journal of Cancer Research*

and Therapeutics, 14(5), pp. 1042–1048. Available at: <https://doi.org/10.4103/0973-1482.187282>.

Hayes, J., Peruzzi, P.P. and Lawler, S. (2014) ‘MicroRNAs in cancer: Biomarkers, functions and therapy’, *Trends in Molecular Medicine*, 20(8), pp. 460–469. Available at: <https://doi.org/10.1016/j.molmed.2014.06.005>.

He, Z., Cen, D., Luo, X., Li, D., Li, P., Liang, L. and Meng, Z. (2013) ‘Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor’, *Medical Oncology*, 30(2), pp. 0–5. Available at: <https://doi.org/10.1007/s12032-013-0557-0>.

Holman, L. and Lu, K. (2012) ‘Genetic Risk and Gynecologic Cancers’, (26), pp. 13–29. Available at: <https://doi.org/10.1016/j.hoc.2011.11.003>.

Horita, K., Kurosaki, H., Nakatake, M., Ito, M., Kono, H. and Nakamura, T. (2019) ‘Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer’, *Biochemical and Biophysical Research Communications*, 516(3), pp. 831–838. Available at: <https://doi.org/10.1016/j.bbrc.2019.06.125>.

Hosseini, J., Mardi Mamaghani, A., Hosseinifar, H., Ali Sadighi Gilani, M., Dadkhah, F. and Sepidarkish, M. (2016) *The influence of ginger (Zingiber officinale) on human sperm quality and DNA fragmentation: A double-blind randomized clinical trial*, *Int J Reprod BioMed*.

Hossian, A.K.M.N., Sajib, M.S., Tullar, P.E., Mikelis, C.M. and Mattheolabakis, G. (2018) ‘Multipronged activity of combinatorial miR-143 and miR-506 inhibits Lung Cancer cell cycle progression and angiogenesis in vitro’, *Scientific Reports*, 8(1). Available at: <https://doi.org/10.1038/s41598-018-28872-2>.

Howe, E.N., Cochrane, D.R. and Richer, J.K. (2012) ‘The miR-200 and miR-221/222 microRNA families: Opposing effects on epithelial identity’, *Journal of Mammary Gland Biology and Neoplasia*, pp. 65–77. Available at: <https://doi.org/10.1007/s10911-012-9244-6>.

Hu, X., Macdonald, D.M., Huettner, P.C., Feng, Z., El Naqa, I.M., Schwarz, J.K., *et al.* (2009) ‘A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer’, *Gynecologic Oncology*, 114(3), pp. 457–464. Available at: <https://doi.org/10.1016/j.ygyno.2009.05.022>.

Hutvagner, G. and Zamore, P.D. (2002) ‘A microRNA in a multiple-turnover RNAi enzyme complex’, *Science*, 297(5589), pp. 2056–2060. Available at: <https://doi.org/10.1126/science.1073827>.

Iorio, M. V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., Taccioli, C., Volinia, S., Liu, C.G., Alder, H., Calin, G.A., Ménard, S. and Croce, C.M. (2007) ‘MicroRNA

signatures in human ovarian cancer', *Cancer Research*, 67(18), pp. 8699–8707. Available at: <https://doi.org/10.1158/0008-5472.CAN-07-1936>.

Jin, A.H. and Wei, Z.L. (2015) 'Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression', *International Journal of Clinical and Experimental Medicine*, 8(8), pp. 13329–13334.

Karst, A.M. and Drapkin, R. (2010) 'Ovarian Cancer Pathogenesis: A Model in Evolution', *Journal of Oncology*, 2010, pp. 1–13. Available at: <https://doi.org/10.1155/2010/932371>.

Kim, S.H. and Baek, K.H. (2021) 'Regulation of cancer metabolism by deubiquitinating enzymes: The warburg effect', *International Journal of Molecular Sciences*. MDPI. Available at: <https://doi.org/10.3390/ijms22126173>.

Kinose, Y., Sawada, K., Nakamura, K. and Kimura, T. (2014) 'The Role of MicroRNAs in Ovarian Cancer', *BioMed Research International*, 2014. Available at: <https://doi.org/10.1155/2014/249393>.

Kitade, Y. and Akao, Y. (2010) 'MicroRNAs and their therapeutic potential for human diseases: MicroRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified mir-143 as an anti-cancer drug', *Journal of Pharmacological Sciences*. Japanese Pharmacological Society, pp. 276–280. Available at: <https://doi.org/10.1254/jphs.10R12FM>.

Klicka, K., Grzywa, T.M., Mielniczuk, A., Klinke, A. and Włodarski, P.K. (2022) 'The role of miR-200 family in the regulation of hallmarks of cancer', *Frontiers in Oncology*. Frontiers Media S.A. Available at: <https://doi.org/10.3389/fonc.2022.965231>.

Kobayashi, M., Salomon, C., Tapia, J., Illanes, S.E., Mitchell, M.D. and Rice, G.E. (2014) *Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 mikroRNA and miR-200*. Available at: <http://www.translational-medicine.com/content/12/1/4>.

Koutsaki, M., Libra, M., Spandidos, D.A. and Zaravinos, A. (2017) 'The miR-200 family in ovarian cancer.', *Oncotarget*, 8(39), pp. 66629–66640. Available at: <https://doi.org/10.18632/oncotarget.18343>.

Kurman, R.J. and Shih, I.M. (2016) 'The dualistic model of ovarian carcinogenesis revisited, revised, and expanded', *American Journal of Pathology*, 186(4), pp. 733–747. Available at: <https://doi.org/10.1016/j.ajpath.2015.11.011>.

Kuroki, L. and Guntupalli, S.R. (2020) 'Treatment of epithelial ovarian cancer', *The BMJ*, 371, pp. 1–20. Available at: <https://doi.org/10.1136/bmj.m3773>.

- Kutuk, O. and Letai, A. (2010) 'Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells', *Cell Death and Differentiation*, pp. 1624–1635. Available at: <https://doi.org/10.1038/cdd.2010.41>.
- Langhe, R., Norris, L., Saadeh, F.A., Blackshields, G., Varley, R., Harrison, A., *et al.* (2015) 'A novel serum microRNA panel to discriminate benign from malignant ovarian disease', *Cancer Letters*, 356(2), pp. 628–636. Available at: <https://doi.org/10.1016/J.CANLET.2014.10.010>.
- Lavacchi, D., Polvani, S., Taddei, A., Scolari, F., Messerini, L., Caliman, E., Moraldi, L., *et al.* (2023) 'KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic adenocarcinoma patients', *Frontiers in Oncology*, 13. Available at: <https://doi.org/10.3389/fonc.2023.1295936>.
- Lee, Y.J., Kim, V., Muth, D.C. and Witwer, K.W. (2015) 'Validated MicroRNA Target Databases: An Evaluation', *Drug Development Research*, 76(7), pp. 389–396. Available at: <https://doi.org/10.1002/ddr.21278>.
- Leeper, K., Garcia, R., Swisher, E., Goff, B., Greer, B. and Paley, P. (2002) 'Pathologic findings in prophylactic oophorectomy specimens in high-risk women', *Gynecologic Oncology*, 87(1), pp. 52–56. Available at: <https://doi.org/10.1006/gyno.2002.6779>.
- De Leo, A., Santini, D., Ceccarelli, C., Santandrea, G., Palicelli, A., Acquaviva, G., Chiarucci, F., Rosini, F., Ravegnini, G., Pession, A., Turchetti, D., Zamagni, C., Perrone, A.M., De Iaco, P., Tallini, G. and de Biase, D. (2021) 'What is new on ovarian carcinoma: Integrated morphologic and molecular analysis following the new 2020 world health organization classification of female genital tumors', *Diagnostics*, 11(4), pp. 1–16. Available at: <https://doi.org/10.3390/diagnostics11040697>.
- Leskelä, S., Leandro-García, L.J., Mendiola, M., Barriuso, J., Inglada-Pérez, L., Muñoz, I., Martínez-Delgado, B., Redondo, A., De Santiago, J., Robledo, M., Hardisson, D. and Rodríguez-Antona, C. (2011) 'The miR-200 family controls β -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients', *Endocrine-Related Cancer*, 18(1), pp. 85–95. Available at: <https://doi.org/10.1677/ERC-10-0148>.
- Li, J., Li, X., Wu, L., Pei, M., Li, H. and Jiang, Y. (2019) 'miR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells', *Cell Biology International*, 43(8), pp. 921–930. Available at: <https://doi.org/10.1002/cbin.11182>.
- Li, J., Zhang, S., Zou, Y., Wu, L., Pei, M. and Jiang, Y. (2020) 'miR-145 promotes miR-133b expression through c-myc and DNMT3A-mediated methylation in ovarian cancer cells',

Journal of Cellular Physiology, 235(5), pp. 4291–4301. Available at: <https://doi.org/10.1002/jcp.29306>.

Li, K.K.W., Pang, J.C.S., Lau, K.M., Zhou, L., Mao, Y., Wang, Y., Poon, W.S. and Ng, H.K. (2013) ‘MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3)’, *Brain Pathology*, 23(4), pp. 413–425. Available at: <https://doi.org/10.1111/bpa.12014>.

Li, T., Lin, L., Liu, Q., Gao, W., Chen, L., Sha, C., Chen, Q., Xu, W., Li, Y. and Zhu, X. (2021) ‘Exosomal transfer of miR-429 confers chemoresistance in epithelial ovarian cancer.’, *American journal of cancer research*, 11(5), pp. 2124–2141.

Li, Xiaowei, Geng, M., Peng, Y., Meng, L. and Lu, S. (2020) ‘Molecular immune pathogenesis and diagnosis of COVID-19’, *Journal of Pharmaceutical Analysis* [Preprint]. Available at: <https://doi.org/10.1016/j.jpha.2020.03.001>.

Li, Xian, Lin, S., Mo, Z., Jiang, J., Tang, H., Wu, C. and Song, J. (2020) ‘CircRNA_100395 inhibits cell proliferation and metastasis in ovarian cancer via regulating miR-1228/p53/epithelial-mesenchymal transition (EMT) axis’, *Journal of Cancer*, 11(3), pp. 599–609. Available at: <https://doi.org/10.7150/jca.35041>.

Li, Y., Yao, L., Liu, F., Hong, J., Chen, L., Zhang, B. and Zhang, W. (2014) ‘Characterization of microRNA expression in serous ovarian carcinoma’, *International Journal of Molecular Medicine*, 34(2), pp. 491–498. Available at: <https://doi.org/10.3892/ijmm.2014.1813>.

Lian, J., Tian, H., Liu, L., Zhang, X.S., Li, W.Q., Deng, Y.M., Yao, G.D., Yin, M.M. and Sun, F. (2010) ‘Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1’, *Cell Death and Disease*, 1(11), pp. 1–12. Available at: <https://doi.org/10.1038/cddis.2010.70>.

Lima, J.F., Cerqueira, L., Figueiredo, C., Oliveira, C. and Azevedo, N.F. (2018) ‘Anti-mikroRNA oligonucleotides: A comprehensive guide for design’, *RNA Biology*, 15(3), pp. 338–352. Available at: <https://doi.org/10.1080/15476286.2018.1445959>.

Liu, G., Sun, Y., Ji, P., Li, X., Cogdell, D., Yang, D., Parker Kerrigan, B.C., Shmulevich, I., Chen, K., Sood, A.K., Xue, F. and Zhang, W. (2014) ‘MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXO1 axis in ovarian cancer’, *Journal of Pathology*, 233(3), pp. 308–318. Available at: <https://doi.org/10.1002/path.4348>.

Liu, J., Dou, Y. and Sheng, M. (2016) ‘Inhibition of microRNA-383 has tumor suppressive effect in human epithelial ovarian cancer through the action on caspase-2 gene’, *Biomedicine and Pharmacotherapy*, 83, pp. 1286–1294. Available at: <https://doi.org/10.1016/j.biopha.2016.07.038>.

- Liu, J., Zhang, Xiaobo, Huang, Y., Zhang, Q., Zhou, J., Zhang, Xiaodi and Wang, X. (2019) 'mir-200b and mir-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases', *Oncology Letters*, 17(2), pp. 1453–1460. Available at: <https://doi.org/10.3892/ol.2018.9745>.
- Liu, M., Shen, C. and Wang, C. (2019) 'Long Noncoding RNA LINC01133 Confers Tumor-Suppressive Functions in Ovarian Cancer by Regulating Leucine-Rich Repeat Kinase 2 as an miR-205 Sponge', *American Journal of Pathology*, 189(11), pp. 2323–2339. Available at: <https://doi.org/10.1016/j.ajpath.2019.07.020>.
- LIU, N., ZHONG, L., ZENG, J., ZHANG, X., YANG, Q., LIAO, D., WANG, Y., CHEN, G. and WANG, Y. (2015) 'Upregulation of microRNA-200a associates with tumor proliferation, CSCs phenotype and chemosensitivity in ovarian cancer', *Neoplasma*, 62(04), pp. 550–559. Available at: https://doi.org/10.4149/neo_2015_066.
- Liu, N., Zhou, C., Zhao, J. and Chen, Y. (2012) 'Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a muc1 aptamer-let-7i chimera', *Cancer Investigation*, 30(8), pp. 577–582. Available at: <https://doi.org/10.3109/07357907.2012.707265>.
- Liu, Yi, Long, T., Zhang, N., Qiao, B., Yang, Q., Luo, Y., Cao, J., Luo, J., Yuan, D., Sun, Y., Li, Y., Yang, Z. and Wang, Z.G. (2020) 'Ultrasound-Mediated Long-Circulating Nanopolymer Delivery of Therapeutic siRNA and Antisense MicroRNAs Leads to Enhanced Paclitaxel Sensitivity in Epithelial Ovarian Cancer Chemotherapy', *ACS Biomaterials Science and Engineering*, 6(7), pp. 4036–4050. Available at: <https://doi.org/10.1021/acsbiomaterials.0c00330>.
- Liu, Yang, Xu, Y., Ding, L., Yu, L., Zhang, B. and Wei, D. (2020) 'LncRNA MEG3 suppressed the progression of ovarian cancer via sponging miR-30e-3p and regulating LAMA4 expression', *Cancer Cell International*, 20(1), pp. 1–15. Available at: <https://doi.org/10.1186/s12935-020-01259-y>.
- Lu, L., Schwartz, P., Scarampi, L., Rutherford, T., Canuto, E.M., Yu, H. and Katsaros, D. (2011) 'MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management', *Gynecologic Oncology*, 122(2), pp. 366–371. Available at: <https://doi.org/10.1016/j.ygyno.2011.04.033>.
- Lu, Y.M., Shang, C., Ou, Y.L., Yin, D., Li, Y.N., Li, X., Wang, N. and Zhang, S.L. (2014) 'miR-200c modulates ovarian cancer cell metastasis potential by targeting zinc finger E-box-binding homeobox 2 (ZEB2) expression', *Medical Oncology*, 31(8). Available at: <https://doi.org/10.1007/s12032-014-0134-1>.

- Luo, H., Zhang, H., Zhang, Z., Zhang, X., Ning, B., Guo, J., Nie, N., Liu, B. and Wu, X. (2009) 'Down-regulated miR-9 and miR-433 in human gastric carcinoma', *Journal of Experimental and Clinical Cancer Research*, 28(1), pp. 1–9. Available at: <https://doi.org/10.1186/1756-9966-28-82>.
- Maddika, S., Ande, S.R., Panigrahi, S., Paranjothy, T., Weglarczyk, K., Zuse, A., Eshraghi, M., Manda, K.D., Wiechec, E. and Los, M. (2007) 'Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy', *Drug Resistance Updates*, 10(1–2), pp. 13–29. Available at: <https://doi.org/10.1016/j.drug.2007.01.003>.
- Mak, C.S.L., Yung, M.M.H., Hui, L.M.N., Leung, L.L., Liang, R., Chen, K., Liu, S.S., Qin, Y., Leung, T.H.Y., Lee, K.F., Chan, K.K.L., Ngan, H.Y.S. and Chan, D.W. (2017) 'MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis', *Molecular Cancer*, 16(1), pp. 1–17. Available at: <https://doi.org/10.1186/s12943-017-0582-2>.
- Marchini, S., Cavalieri, D., Beltrame, L., Romualdi, C., Katsaros, D., Scarampi, L., Marchini, Sergio, Cavalieri, Duccio, Fruscio, R., Calura, E., Garavaglia, D., Fuso Nerini, I., Mangioni, C. and Cattoretti, G. (2011) 'Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections', *Lancet Oncology*, 12, pp. 273–285. Available at: <https://doi.org/10.1016/S1470>.
- Martins, F.C., Couturier, D.L., Paterson, A., Karnezis, A.N., Chow, C., Nazeran, T.M., *et al.* (2020) 'Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium', *British Journal of Cancer*, 123(5), pp. 793–802. Available at: <https://doi.org/10.1038/s41416-020-0900-0>.
- Masoodi, T., Siraj, S., Siraj, A.K., Azam, S., Qadri, Z., Parvathareddy, S.K., Tulbah, A., *et al.* (2020) 'Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases', *British Journal of Cancer*, 122(8), pp. 1219–1230. Available at: <https://doi.org/10.1038/s41416-020-0763-4>.
- Mateescu, B., Batista, L., Cardon, M., Gruosso, T., De Feraudy, Y., Mariani, O., Nicolas, A., Meyniel, J.P., Cottu, P., Sastre-Garau, X. and Mechta-Grigoriou, F. (2011) 'MiR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response', *Nature Medicine*, pp. 1627–1635. Available at: <https://doi.org/10.1038/nm.2512>.
- Matthews, B.G., Bowden, N.A. and Wong-Brown, M.W. (2021) 'Epigenetic mechanisms and therapeutic targets in chemoresistant high-grade serous ovarian cancer', *Cancers*, 13(23), pp. 1–18. Available at: <https://doi.org/10.3390/cancers13235993>.

- Miao, S., Wang, J., Xuan, L. and Liu, X. (2020) 'LncRNA TTN-AS1 acts as sponge for miR-15b-5p to regulate FBXW7 expression in ovarian cancer', *BioFactors*, 46(4), pp. 600–607. Available at: <https://doi.org/10.1002/biof.1622>.
- Miles, G.D., Seiler, M., Rodriguez, L., Rajagopal, G. and Bhanot, G. (2012) 'Identifying microRNA/mRNA dysregulations in ovarian cancer', *BMC Research Notes*. Available at: <https://doi.org/10.1186/1756-0500-5-164>.
- Naeini, M.M. and Ardekani, A.M. (2009) 'Noncoding RNAs and Cancer.', *Avicenna journal of medical biotechnology*, 1(2), pp. 55–70.
- Nam, E.J., Yoon, H., Kim, S.W., Kim, H., Kim, Y.T., Kim, J.H., Kim, J.W. and Kim, S. (2008) 'MicroRNA expression profiles in serous ovarian carcinoma', *Clinical Cancer Research*, 14(9), pp. 2690–2695. Available at: <https://doi.org/10.1158/1078-0432.CCR-07-1731>.
- Pérez-Tomás, R. and Pérez-Guillén, I. (2020) 'Lactate in the tumor microenvironment: An essential molecule in cancer progression and treatment', *Cancers*. MDPI AG, pp. 1–29. Available at: <https://doi.org/10.3390/cancers12113244>.
- Piek, J.M.J., Van Diest, P.J., Zweemer, R.P., Jansen, J.W., Poort-Keesom, R.J.J., *et al.* (2001) 'Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer', *Journal of Pathology*, 195(4), pp. 451–456. Available at: <https://doi.org/10.1002/path.1000>.
- Prisilei, S., Martinelli, E., Mariani, M., Raspaglio, G., Sieber, S., Ferrandina, G., *et al.* (2013) 'MiR-200c and HuR in ovarian cancer', *BMC Cancer*, 13(1), p. 1. Available at: <https://doi.org/10.1186/1471-2407-13-72>.
- Raja, F.A., Chopra, N. and Ledermann, J.A. (2012) 'Optimal first-line treatment in ovarian cancer', *Annals of Oncology*, 23(SUPPL. 10). Available at: <https://doi.org/10.1093/annonc/mds315>.
- Raniolo, S., Unida, V., Vindigni, G., Stolfi, C., Iacovelli, F., Desideri, A. and Biocca, S. (2021) 'Combined and selective miR-21 silencing and doxorubicin delivery in cancer cells using tailored DNA nanostructures', *Cell Death and Disease*, 12(1), pp. 3–11. Available at: <https://doi.org/10.1038/s41419-020-03339-3>.
- Ren, T., Sun, T.T., Wang, S., Sun, J., Xiang, Y., Shen, K. and Lang, J.H. (2018) 'Clinical analysis of chemo-resistance risk factors in endometriosis associated ovarian cancer', *Journal of Ovarian Research*, 11(1), pp. 1–7. Available at: <https://doi.org/10.1186/s13048-018-0418-8>.
- Resnick, K.E., Alder, H., Hagan, J.P., Richardson, D.L., Croce, C.M. and Cohn, D.E. (2009) 'The detection of differentially expressed microRNAs from the serum of ovarian cancer

patients using a novel real-time PCR platform', *Gynecologic Oncology*, 112(1), pp. 55–59.

Available at: <https://doi.org/10.1016/j.ygyno.2008.08.036>.

Rooij, E. and Kauppinen, S. (2014) 'Development of micro RNA therapeutics is coming of age', *EMBO Molecular Medicine*, 6(7), pp. 851–864. Available at: <https://doi.org/10.15252/emmm.201100899>.

Ruan, K., Fang, X. and Ouyang, G. (2009) 'MicroRNAs: Novel regulators in the hallmarks of human cancer', *Cancer Letters*, 285(2), pp. 116–126. Available at: <https://doi.org/10.1016/j.canlet.2009.04.031>.

Salem, M., Shan, Y., Bernaud, S. and Peng, C. (2019) 'miR-590-3p targets cyclin G2 and FOXO3 to promote ovarian cancer cell proliferation, invasion, and spheroid formation', *International Journal of Molecular Sciences*, 20(8). Available at: <https://doi.org/10.3390/ijms20081810>.

Sasaki, H., Sheng, Y.L., Kotsuji, F. and Tsang, B.K. (2000) 'Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells', *Cancer Research*, 60(20), pp. 5659–5666.

Sève, P. and Dumontet, C. (2008) 'Is class III β -tubulin a predictive factor in patients receiving tubulin-binding agents?', *The Lancet Oncology*, 9(2), pp. 168–175. Available at: [https://doi.org/10.1016/S1470-2045\(08\)70029-9](https://doi.org/10.1016/S1470-2045(08)70029-9).

Shahruzaman, S.H., Fakurazi, S. and Maniam, S. (2018) 'Targeting energy metabolism to eliminate cancer cells', *Cancer Management and Research*. Dove Medical Press Ltd, pp. 2325–2335. Available at: <https://doi.org/10.2147/CMAR.S167424>.

Shell, S., Park, S.M., Radjabi, A.R., Schickel, R., Kistner, E.O., Jewell, D.A., *et al.* (2007) 'Let-7 expression defines two differentiation stages of cancer', *Proceedings of the National Academy of Sciences of the United States of America*, 104(27), pp. 11400–11405. Available at: <https://doi.org/10.1073/pnas.0704372104>.

Shi H, Shen H, Xu Juan, Zhao S, Yao S and Jiang N (2018) 'miR-143-3p - SKOV3', *Am J Transl Res*, 10(3), pp. 866–874. Available at: <https://e-century.us/files/ajtr/10/3/ajtr0070712.pdf> (Accessed: 14 May 2024).

Suardi, R.B., Ysrafil, Y., Sesotiyosari, S.L., Martien, R., Wardana, T., Astuti, I. and Haryana, S.M. (2020) 'The effects of combination of mimic miR-155-5p and antagonist miR-324-5p encapsulated chitosan in ovarian cancer SKOV3', *Asian Pacific Journal of Cancer Prevention*, 21(9), pp. 2603–2608. Available at: <https://doi.org/10.31557/APJCP.2020.21.9.2603>.

- Sun, Q., Zou, X., Zhang, T., Shen, J., Yin, Y. and Xiang, J. (2014) 'The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer', *Gynecologic Oncology*, 132(3), pp. 730–738. Available at: <https://doi.org/10.1016/j.ygyno.2014.01.047>.
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) 'Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries', *CA: A Cancer Journal for Clinicians*, 71(3), pp. 209–249. Available at: <https://doi.org/10.3322/caac.21660>.
- Suo, H.-B., Zhang, K.-C. and Zhao, J. (2018) 'MiR-200a promotes cell invasion and migration of ovarian carcinoma by targeting PTEN.', *European review for medical and pharmacological sciences*, 22(13), pp. 4080–4089. Available at: https://doi.org/10.26355/eurev_201807_15398.
- Tavassoli, F. and Devilee, P. (2003) *Pathology and Genetics of Tumours of the Breast and Female Genital Organs*,. International Agency for Research on Cancer World Health Organization, IAPS Press, Lyon, France.
- Thomadaki, H. and Scorilas, A. (2006) 'BCL2 family of apoptosis-related genes: Functions and clinical implications in cancer', *Critical Reviews in Clinical Laboratory Sciences*, 43(1), pp. 1–67. Available at: <https://doi.org/10.1080/10408360500295626>.
- Tommasi, S., Mangia, A., Lacalamita, R., Bellizzi, A., Fedele, V., Chiriatti, A., *et al.* (2007) 'Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β -tubulins', *International Journal of Cancer*, 120(10), pp. 2078–2085. Available at: <https://doi.org/10.1002/ijc.22557>.
- Tsuda, N., Kawano, K., Efferson, C.L. and Ioannides, C.G. (2005) 'Synthetic microRNA and double-stranded RNA targeting the 3'-untranslated region of HER-2/neu mRNA inhibit HER-2 protein expression in ovarian cancer cells', *International Journal of Oncology*, 27(5), pp. 1299–1306. Available at: <https://doi.org/10.3892/ijo.27.5.1299>.
- Tsujino, T., Sugito, N., Taniguchi, K., Honda, R., Komura, K., Yoshikawa, Y., *et al.* (2019) 'MicroRNA-143/Musashi-2/KRAS cascade contributes positively to carcinogenesis in human bladder cancer', *Cancer Science*, 110(7), pp. 2189–2199. Available at: <https://doi.org/10.1111/cas.14035>.
- Vandghanooni, S., Eskandani, M., Barar, J. and Omid, Y. (2018) 'AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells', *Nanomedicine*, 13(21). Available at: <https://doi.org/10.2217/nmm-2018-0205>.
- Vandghanooni, S., Eskandani, M., Barar, J. and Omid, Y. (2020) 'Antisense LNA-loaded nanoparticles of star-shaped glucose-core PCL-PEG copolymer for enhanced inhibition of

oncomiR-214 and nucleolin-mediated therapy of cisplatin-resistant ovarian cancer cells', *International Journal of Pharmaceutics*, 573, p. 118729. Available at: <https://doi.org/10.1016/j.ijpharm.2019.118729>.

Vang, S., Wu, H.T., Fischer, A., Miller, D.H., MacLaughlan, S., Douglass, E., Steinhoff, M., Collins, C., Smith, P.J.S., Brard, L. and Brodsky, A.S. (2013) 'Identification of Ovarian Cancer Metastatic mikroRNAs', *PLoS ONE*, 8(3). Available at: <https://doi.org/10.1371/journal.pone.0058226>.

Vilming Elgaaen, B., Olstad, O.K., Haug, K.B.F., Brusletto, B., Sandvik, L., Staff, A.C., Gautvik, K.M. and Davidson, B. (2014) 'Global mikroRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed mikroRNAs including miR-200c-3p as a prognostic marker', *BMC Cancer*, 14(1). Available at: <https://doi.org/10.1186/1471-2407-14-80>.

Wang, L., Mezencev, R., Švajdler, M., Benigno, B.B. and McDonald, J.F. (2014) 'Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells', *Gynecologic Oncology*, 134(1), pp. 96–103. Available at: <https://doi.org/10.1016/j.ygyno.2014.04.055>.

Wang, R., Kang, Y., Löhr, C. V., Fischer, K.A., Bradford, C.S., Johnson, G., Dashwood, W.M., Williams, D.E., Ho, E. and Dashwood, R.H. (2016) 'Reciprocal regulation of BMF and BIRC5 (Survivin) linked to Eomes overexpression in colorectal cancer', *Cancer Letters*, 381(2), pp. 341–348. Available at: <https://doi.org/10.1016/j.canlet.2016.08.008>.

Wang, S., Li, M.Y., Liu, Y., Vlantis, A.C., Chan, J.Y.K., Xue, L., *et al.* (2020) 'The role of microRNA in cisplatin resistance or sensitivity', *Expert Opinion on Therapeutic Targets*, 0(0), pp. 885–897. Available at: <https://doi.org/10.1080/14728222.2020.1785431>.

Wang, X., Zhang, H., Bai, M., Ning, T., Ge, S., Deng, T., Liu, R., Zhang, L., Ying, G. and Ba, Y. (2018) 'Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer', *Molecular Therapy*, 26(3), pp. 774–783. Available at: <https://doi.org/10.1016/j.ymthe.2018.01.001>.

Wang, Y., Zeng, G. and Jiang, Y. (2020) 'The emerging roles of MiR-125b in cancers', *Cancer Management and Research*. Dove Medical Press Ltd, pp. 1079–1088. Available at: <https://doi.org/10.2147/CMAR.S232388>.

Wang, Z. (2011) 'The Guideline of the Design and Validation of MikroRNA Mimics BT - MicroRNA and Cancer: Methods and Protocols', *MicroRNA and Cancer*, 676, pp. 211–223. Available at: <https://doi.org/10.1007/978-1-60761-863-8>.

- Webb, P.M. and Jordan, S.J. (2017) 'Epidemiology of epithelial ovarian cancer', *Best Practice and Research: Clinical Obstetrics and Gynaecology*, 41, pp. 3–14. Available at: <https://doi.org/10.1016/j.bpobgyn.2016.08.006>.
- Woodward, E.R., Sleightholme, H. V., Considine, A.M., Williamson, S., McHugo, J.M. and Cruger, D.G. (2007) 'Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective', *BJOG: An International Journal of Obstetrics and Gynaecology*, 114(12), pp. 1500–1509. Available at: <https://doi.org/10.1111/j.1471-0528.2007.01499.x>.
- Wu, J., Liu, Z., Shao, C., Gong, Y., Hernando, E., Lee, P., Narita, M., Muller, W., Liu, J. and Wei, J.J. (2011) 'HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes', *Cancer Research*, 71(2), pp. 349–359. Available at: <https://doi.org/10.1158/0008-5472.CAN-10-2550>.
- Wuerkenbieke, D., Wang, J., Li, Y. and Ma, C. (2015) 'mikroRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation.', *Archives of gynecology and obstetrics*, 292(5), pp. 1109–16. Available at: <https://doi.org/10.1007/s00404-015-3742-x>.
- Xia, B., Yang, S., Liu, T. and Lou, G. (2015) 'miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6', *Molecular Cancer*, 14(1), pp. 1–13. Available at: <https://doi.org/10.1186/s12943-015-0322-4>.
- Xie, X., Huang, Y., Chen, L. and Wang, J. (2018) 'miR-221 regulates proliferation and apoptosis of ovarian cancer cells by targeting BMF', *Oncology Letters*, 16(5), pp. 6697–6704. Available at: <https://doi.org/10.3892/ol.2018.9446>.
- Xu, L., Cai, J., Yang, Q., Ding, H., Wu, L., Li, T. and Wang, Z. (2013) 'Prognostic significance of several biomarkers in epithelial ovarian cancer: A meta-analysis of published studies', *Journal of Cancer Research and Clinical Oncology*, 139(8), pp. 1257–1277. Available at: <https://doi.org/10.1007/s00432-013-1435-z>.
- Xu, S., Tao, Z., Hai, B., Liang, H., Shi, Y., Wang, T., *et al.* (2016) 'miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint', *Nature Communications*, 7. Available at: <https://doi.org/10.1038/ncomms11406>.
- Xu, S., Xu, P., Wu, W., Ou, Y., Xu, J., Zhang, G., Li, J. and Xu, G. (2014) 'The Biphasic Expression Pattern of miR-200a and E-cadherin in Epithelial Ovarian Cancer and its Correlation with Clinicopathological Features', *Current Pharmaceutical Design*, 20(11), pp. 1888–1895. Available at: <https://doi.org/10.2174/13816128113199990523>.

- Xue, C.L., Liu, H.G., Li, B.Y., He, S.H. and Yue, Q.F. (2019) 'Physcion 8-O- β -glucopyranoside exhibits anti-growth and anti-metastatic activities in ovarian cancer by downregulating miR-25', *European Review for Medical and Pharmacological Sciences*, pp. 5101–5112. Available at: https://doi.org/10.26355/eurev_201906_18174.
- Yan, J., Jiang, J.Y., Meng, X.N., Xiu, Y.L. and Zong, Z.H. (2016) 'MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression', *Journal of Experimental and Clinical Cancer Research*, 35(1), pp. 1–10. Available at: <https://doi.org/10.1186/s13046-016-0307-1>.
- Yang, H., Kong, W., He, L., Zhao, J.J., O'Donnell, J.D., Wang, J., Wenham, R.M., Coppola, D., Kruk, P.A., Nicosia, S. V. and Cheng, J.Q. (2008) 'MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN', *Cancer Research*, 68(2), pp. 425–433. Available at: <https://doi.org/10.1158/0008-5472.CAN-07-2488>.
- Yang, Y., Li, S., Sun, Y., Zhang, D., Zhao, Z. and Liu, L. (2019) 'Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2', *OncoTargets and Therapy*, 12, pp. 897–906. Available at: <https://doi.org/10.2147/OTT.S187015>.
- Ye, W., Ni, Z., Yicheng, S., Pan, H., Huang, Y., Xiong, Y. and Liu, T. (2019) 'Anisomycin inhibits angiogenesis in ovarian cancer by attenuating the molecular sponge effect of the lncRNA-Meg3/miR-421/PDGFR α axis', *International Journal of Oncology*, pp. 1296–1312. Available at: <https://doi.org/10.3892/ijo.2019.4887>.
- Yin, H., Sun, Y., Wang, X., Park, J., Zhang, Y., Li, M., Yin, J., Liu, Q. and Wei, M. (2015) 'Progress on the relationship between miR-125 family and tumorigenesis', *Experimental Cell Research*. Academic Press Inc., pp. 252–260. Available at: <https://doi.org/10.1016/j.yexcr.2015.09.015>.
- Yin, M., Lü, M., Yao, G., Tian, H., Lian, J., Liu, L., Liang, M., Wang, Y. and Sun, F. (2012) 'Transactivation of microRNA-383 by steroidogenic factor-1 promotes estradiol release from mouse ovarian granulosa cells by targeting RBMS1', *Molecular Endocrinology*, 26(7), pp. 1129–1143. Available at: <https://doi.org/10.1210/me.2011-1341>.
- Ysrafil, Y., Astuti, I., Anwar, S.L., Martien, R., Sumadi, F.A.N., Wardhana, T. and Haryana, S.M. (2020) 'MicroRNA-155-5p Diminishes in Vitro Ovarian Cancer Cell Viability by Targeting HIF1 α Expression', *Advanced Pharmaceutical Bulletin*, 10(4), pp. 630–637. Available at: <https://doi.org/10.34172/apb.2020.076>.
- Yu, H., Su, J., Xu, Y., Kang, J., Li, H., Zhang, L., Yi, H., Xiang, X., Liu, F. and Sun, L. (2011) 'p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing

ubiquitinated proteins', *European Journal of Cancer*, 47(10), pp. 1585–1594. Available at: <https://doi.org/10.1016/j.ejca.2011.01.019>.

Yuan, J., Li, T., Yi, K. and Hou, M. (2020) 'The suppressive role of miR-362-3p in epithelial ovarian cancer', *Heliyon*, 6(7), pp. 1–7. Available at: <https://doi.org/10.1016/j.heliyon.2020.e04258>.

Záveský, L., Jandáková, E., Weinberger, V., Hanzíková, V., Slanař, O. and Kohoutová, M. (2022) 'Ascites in ovarian cancer: MicroRNA deregulations and their potential roles in ovarian carcinogenesis', *Cancer Biomarkers*, 33(1), pp. 1–16. Available at: <https://doi.org/10.3233/CBM-210219>.

Zeng, Y., Wagner, E.J. and Cullen, B.R. (2002) 'Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells', *Molecular Cell*, 9(6), pp. 1327–1333. Available at: [https://doi.org/10.1016/S1097-2765\(02\)00541-5](https://doi.org/10.1016/S1097-2765(02)00541-5).

Zhang, K.-C., Xi, H.-Q., Cui, J.-X., Shen, W.-S., Li, J.-Y., Wei, B. and Chen, L. (2015) 'Hemolysis-free plasma miR-214 as novel biomarker of gastric cancer and is correlated with distant metastasis.', *American journal of cancer research*, 5(2), pp. 821–9.

Zhang, L., Volinia, S., Bonome, T., Calin, G.A., Greshock, J., Yang, N., Liu, C.G., Giannakakis, A., *et al.* (2008) 'Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer', *Proceedings of the National Academy of Sciences of the United States of America*, 105(19), pp. 7004–7009. Available at: <https://doi.org/10.1073/pnas.0801615105>.

Zhang, S., Zhang, J.Y., Lu, L.J., Wang, C.H. and Wang, L.H. (2017) 'MiR-630 promotes epithelial ovarian cancer proliferation and invasion via targeting KLF6', *European review for medical and pharmacological sciences*, 21(20), pp. 4542–4547.

Zhang, W., Wang, Q., Yu, M., Wu, N. and Wang, H. (2014) 'MicroRNA-145 function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer', *Technology in Cancer Research and Treatment*, 13(2), pp. 161–168. Available at: <https://doi.org/10.7785/tcrt.2012.500367>.

Zhang, X. yan, Li, Y. feng, Ma, H. and Gao, Y. he (2020) 'Regulation of MYB mediated cisplatin resistance of ovarian cancer cells involves miR-21-wnt signaling axis', *Scientific Reports*, 10(1), pp. 1–8. Available at: <https://doi.org/10.1038/s41598-020-63396-8>.

Zhang, X.J., Ye, H., Zeng, C.W., He, B., Zhang, H. and Chen, Y.Q. (2010) 'Dysregulation of miR-15a and miR-214 in human pancreatic cancer', *Journal of Hematology and Oncology*, 3, pp. 1–9. Available at: <https://doi.org/10.1186/1756-8722-3-46>.

- Zhang, Y., Ai, H., Fan, X., Chen, S., Wang, Y. and Liu, L. (2020) ‘Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1’, *Biological Research*, 53(1), pp. 1–10. Available at: <https://doi.org/10.1186/s40659-020-00286-3>.
- Zheng, H., Zhang, L., Zhao, Y., Yang, D., Song, F., Wen, Y., Hao, Q., Hu, Z., Zhang, W. and Chen, K. (2013) ‘Plasma mikroRNAs as diagnostic and prognostic biomarkers for ovarian cancer’, *PLoS ONE*, 8(11). Available at: <https://doi.org/10.1371/journal.pone.0077853>.
- Zhou, X., Jiang, J. and Guo, S. (2021) ‘Hsa_circ_0004712 downregulation attenuates ovarian cancer malignant development by targeting the miR-331-3p/FZD4 pathway’, *Journal of Ovarian Research*, 14(1). Available at: <https://doi.org/10.1186/s13048-021-00859-0>.
- Zhou, Y., An, Q., Guo, R. xia, Qiao, Y. huan, Li, L. xia, Zhang, X. yan and Zhao, X. lan (2017) ‘miR424-5p functions as an anti-oncogene in cervical cancer cell growth by targeting KDM5B via the Notch signaling pathway’, *Life Sciences*, 171, pp. 9–15. Available at: <https://doi.org/10.1016/j.lfs.2017.01.006>.
- Zhu, C.L. and Gao, G.S. (2014) ‘miR-200a overexpression in advanced ovarian carcinomas as a prognostic indicator’, *Asian Pacific Journal of Cancer Prevention*, 15(20), pp. 8595–8601. Available at: <https://doi.org/10.7314/APJCP.2014.15.20.8595>.
- Zhu, T., Gao, W., Chen, X., Zhang, Y., Wu, M., Zhang, P. and Wang, S. (2017) ‘A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer’, *International Journal of Gynecological Cancer*, 27(1), pp. 3–10. Available at: <https://doi.org/10.1097/IGC.0000000000000846>.
- Zhu, W., Xiao, X. and Chen, J. (2021) ‘Silencing of the long noncoding RNA LINC01132 alleviates the oncogenicity of epithelial ovarian cancer by regulating the microRNA-431-5p/SOX9 axis’, *International Journal of Molecular Medicine*. Available at: <https://doi.org/10.3892/ijmm.2021.4984>.